tbuckley/cabot-search huggingface dataset:
THU0204 The (un)coupling of inflammation and destruction in patients treated with rhil-1ra
Authors: AM Van Gestel, PL Van Riel, C Lindsay, JM Robinson
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Previous studies have shown that recombinant human interleukin-1 receptor antagonist (rhIL-1ra) has an effect on RA disease activity and on the progression of radiographic damage. In animal models an uncoupling between joint inflammation and joint destruction is found with rhIL-1ra. We hypothesised that in case of uncoupling the association found between these disease aspects would be different for patients treated with rhIL-1ra versus placebo. <h3>Objectives</h3> To study the coupling between disease activity and radiographic damage in a 24-week placebo controlled trial of rhIL-1ra in 472 RA patients. <h3>Methods</h3> Since no clear dose-response relation has been shown for the 3 active groups (30, 75, 150 mg/d), these groups were combined for the analyses. Models were made to explain the Larsen progression score (LPS) by treatment group (TG), EULAR response (EUL), and TG*EUL interaction term. In a different model the EUL was replaced with the endpoint DAS28. <h3>Results</h3> At 24 weeks LPS was partly explained by TG (p = 0.02) but not by EUL. Exchanging EUL for DAS28, LPS was partly explained by DAS28 (p &lt; 0.001) and TG*DAS28 (p = 0.02). The higher the DAS28 the higher the LPS, and this was more pronounced in the placebo group. <h3>Conclusion</h3> At 24 weeks the association between x-ray progression and inflammation is more pronounced in the placebo group, suggesting an uncoupling with active rhIL-1ra treatment. Further data analyses, including the 24 week extension of the trial, might confirm these findings. <h3>Reference</h3> Breshnihan B, Alvaro-Gracia JM, Cobby M, <i>et al</i>. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196–204
HP0007 The haq index – relations to difficulty in daily activities
Authors: KU Nordh, U Nordenskiöld
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> The objectives were to make an analysis of the HAQ disability index concerning if the patients marked their difficulty in the answere alternatives "no, any or much difficulty" and "using assistive devices" as well as if their assistive devices were in use at home. The methods One hundred and eighteen patients, with rheumatoid arthritis have attended in the program "Early Arthritis" which all have been at their two year control at Karolinska hospital. One hundred and eighteen of 124 patients were included in this study, 30 male and 88 female with the mean age of 53 years. The patients have marked their perceived difficulty in the HAQ seven times during two years and filled in a checklist with assistive devices. In the HAQ the scale steps are 0 = no difficulty, 1 = with any difficulty, 2 = with much difficulty, 2 = with assistive devices and 3 = unable to do. Both "much difficulty" and "using assistive devices" are scored with the scale step 2. The results showed that 99 of 118 patients had assistive devices at home, 20 men had 4.6 assistive devices and 79 women had 10 assistive devices per person. In spite of that 97% of the devices were in use by the men and 95% were in use by the women, seventeen men and 57 women had never filled in the answere alternative "with assistive devices" in the HAQ, even though they were using the devices. If the men and the women had filled in the alternative "with assistive devices", an increased HAQ index should have been identified. The mean value had increased from 0,28 to 0,5 for the men and for the women the mean value had increased from 0,56 to 0,89. The conclusion The HAQ index is not reliable enough to show the level of patients perceived difficulty in daily activities in relation to using assistive devices. The scale step 2 is used for both "much difficulty" and for "with assistive devices" and the patients in this study had not filled in the alternative "with assistive devices".&nbsp;The HAQ index mixes two different aspects of disability, dependence in terms of use of assistive devices and perceived difficulty. <h3>References</h3> Fries JF. The assessment of disability; from first to future principles. Br J Rheumatol. 1983; <b>22</b>(3 Suppl):48–58 Guillemin F, Briacon S, Pourel J. Validity and discriminant ability of HAQ Functional Index in early rheumatoid arthritis. Disabil Rehabil.1992;14:71–7 Tennant A, Hillman M, Fear J. Are we making the most of The Stanford Health Assessment Questionnaire? Br J Rheumatol. 1996;35:574–8 Nordenskiöld U, Grimby G. Assessment of disability in women with rheumatoid arthritis in relation to grip force and pain. Disabil Rehabil. 1997;19:13–9
Abstract 14870: Meta-Analysis of the Efficacy, Safety and Cost-Benefit of Direct Oral Anticoagulation for Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients Post-Hospitalization
Authors: Olivia Lamping, Ahmed Abdel-Latif, Meenakshi Bhalla, Susan S Smyth, Vikas Bhalla
Journal: Circulation (2019)

Medically ill patients remain at risk of venous thromboembolism (VTE) for up to 6 weeks after hospital discharge due to factors such as immobilization and inflammation. We conducted a meta-analysis...
Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival
Authors: Dominik Bettinger, Lukas Sturm, Lena Pfaff, Felix Hahn, Roman Kloeckner, Lara Volkwein, Michael Praktiknjo, Yong Lv, Guohong Han, Jan Patrick Huber, Tobias Boettler, Marlene Reincke, Christoph Klinger, Karel Caca, Hauke Heinzow, Leon Louis Seifert, Karl Heinz Weiss, Christian Rupp, Felix Piecha, Johannes Kluwe, Alexander Zipprich, Hendrik Luxenburger, Christoph Neumann-Haefelin, Arthur Schmidt, Christian Jansen, Carsten Meyer, Frank E. Uschner, Maximilian J. Brol, Jonel Trebicka, Martin Rössle, Robert Thimme, Michael Schultheiss
Journal: Journal of Hepatology (2021)
The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis
Authors: Lina Badimon, Gemma Vilahur, Bianca Rocca, Carlo Patrono
Journal: Cardiovascular Research (2021)

Abstract Arachidonic acid is one of the most abundant and ubiquitous ω-6 polyunsaturated fatty acid, present in esterified form in the membrane phospholipids of all mammalian cells and released from phospholipids by several phospholipases in response to various activating or inhibitory stimuli. Arachidonic acid is the precursor of a large number of enzymatically and non-enzymatically derived, biologically active autacoids, including prostaglandins (PGs), thromboxane (TX) A2, leukotrienes, and epoxyeicosatetraenoic acids (collectively called eicosanoids), endocannabinoids and isoprostanes, respectively. Eicosanoids are local modulators of the physiological functions and pathophysiological roles of blood vessels and platelets. For example, the importance of cyclooxygenase (COX)-1-derived TXA2 from activated platelets in contributing to primary haemostasis and atherothrombosis is demonstrated in animal and human models by the bleeding complications and cardioprotective effects associated with low-dose aspirin, a selective inhibitor of platelet COX-1. The relevance of vascular COX-2-derived prostacyclin (PGI2) in endothelial thromboresistance and atheroprotection is clearly shown by animal and human models and by the adverse cardiovascular effects exerted by COX-2 inhibitors in humans. A vast array of arachidonic acid-transforming enzymes, downstream synthases and isomerases, transmembrane receptors, and specificity in their tissue expression make arachidonic acid metabolism a fine-tuning system of vascular health and disease. Its pharmacological regulation is central in human cardiovascular diseases, as demonstrated by biochemical measurements and intervention trials.
Normal-pressure hydrocephalus
Authors: L. P. Hinterbuchner
Journal: JAMA (1990)

<h3>To the Editor.—</h3> I enjoyed the article about normal-pressure hydrocephalus by Dr Friedland<sup>1</sup>and the editorial comments by Dr Clarfield.<sup>2</sup>While the term "treatable dementia" is fine, all of us who have been in the practice of neurology long enough will remember many failures of shunt procedures to balance each success. Given the pitfalls of diagnosis and especially the difficulty of selecting the most suitable patients for shunt procedures, it is curious that Drs Friedland and Clarfield omitted any mention of a scinticisternogram. Either a positive or a negative comment would have been useful. If negative, the potential candidates for shunt could be spared a spinal tap and the operator could avoid exposure to radioisotopes. If positive, surely the information could be confirmatory to the diagnosis or at least linked to eventual beneficial outcome?
AB0169 ENHANCED PLATELET ACTIVATION AMONG PATIENTS WITH SYSTEMIC SCLEROSIS
Authors: N. Solomonidi, P. Vlachoyiannopoulos, P. Koufargyris, A. Karageorgos, E. Theotikos, E. Giamarellos-Bourboulis, A. Elezoglou
Journal: Annals of the Rheumatic Diseases (2020)

Background: The function of platelets (PLT), which can serve as reservoirs of transforming growth beta, leads to the question whether they are activated in systemic sclerosis (SSc) to such an extent as to associate with clinical severity. Objectives: To compare the level of PLT activation in SSc and to correlate with physical findings Methods: Blood was sampled from 12 patients participating in the randomized clinical trial LIGHT (ClinicalTrials.gov NCT040045743) evaluating the safety and efficacy of bermekimab in SSc. Patients had to meet the 2013 ACR/EULAR classification criteria and have a modified Rodnan skin score (mRSS) between 15 and 40. Sampling was done before allocation to treatment. Nil patient was on DMARDs. Ten healthy donors were used for comparison. Citrated whole blood was exposed to 0.1 mM adenosine diphosphate (ADP) to stimulate PLT. Total platelet populations were defined as CD42b-positive population; P-selectin (CD62p) served as an activation marker. Results: Expression of 42b(+)/62p(+) PLT was greater among patients (Figure 1). Mean fluorescence intensity (MFI) of 42b(+)/62p(+) PLTs was 0.16 +/- 0.08 in comparators and 0.51 +/- 0.07 in patients (p= 0.015). Negative correlation was found between the expression of 42b(+)/62p(+) on PLT and mRSS (r= -0.73, p= 0.028). Patients with grade 2 findings at capillaroscopy had greater expression of 42b(+)/62p(+) than patients with grade 3 findings (45.9 +/- 7.2 % vs 27.2 +/- 6.7 %; p: 0.041). Conclusion: PLTs are greatly activated in SSc and this is associated with disease progression. Findings suggest that this activation is greater at less severe patients. References: [1]Morel A, Rywaniak J, Bijak M, Miller E, Niwald M, Saluk J. Flow cytometric analysis reveals the high levels of platelet activation parameters in circulation of multiple sclerosis patients Mol Cell Biochem. 2017;430:69-80. doi: 10.1007/s11010-017-2955-7 Disclosure of Interests: None declared
Abstract 14936: Prognosis of Breast Cancer and Heart Failure in Postmenopausal Women
Authors: Phillip H Lam, Ana Barac, Anju Nohria, Kerryn Reding, Gregg C Fonarow, Kathy Pan, Helen Sheriff, Charity Morgan, Samer S Najjar, Rowan Chlebowski, Liviu Klein, Charles B Eaton, Barbara V Howard, Ali Ahmed, Selma Mohammed
Journal: Circulation (2019)

Introduction: Heart failure (HF) and breast cancer are highly prevalent and are two of the leading causes of death in postmenopausal women. Few studies to date have examined the impact of HF and br...
Abstract 16738: Reendothelization of a Pediatric-Sized Decellularized Heart Using Cells Grown in a Closed Expansion System
Authors: Camila T Hochman-Mendez, Fernanda C Mesquita, Jacquelynn T Morrissey, Karis R Tang-Quan, Yutao T Xi, Po T Feng-Lee, Luiz C Sampaio, Doris A Taylor
Journal: Circulation (2018)

Background: Coagulation is a significant issue in bioengineering of vascularized tissues. Reendothelization is a strategy commonly used to prevent it in bioartificial organs. However, the large number of cells required for full coverage of blood vessels in a human-sized heart is a bottleneck in this field. Closed cell expansion systems (e.g., Quantum Cell Expansion System, QES) may provide a solution to this issue. The goal of this work was to reendothelize a pediatric-sized decellularized heart using human induced pluripotent stem cell-derived endothelial cells (hiPSC-dEC). Methods: hiPSC-dEC were expanded using the QES and cultivated with decellularized cardiac patches or perfused into whole decellularized rabbit hearts. Reendothelized cardiac patches and whole hearts were evaluated by live/dead staining, histology, scanning electron microscopy (SEM) and immunofluorescence. Results: Our results demonstrated that QES induced exponential iPSC-dEC growth, producing 36.14x10e7 ± 2.34x10e7 cells after 5-9 days (n=13). After cell expansion, these cells expressed von Willebrand Factor (vWF) and CD31, maintaining the phenotype of the endothelial cells. They also retained the capacity of cell-cell interaction evaluated by VE-cadherin staining. Rabbit hearts (8 ± 1.3 grams) were decellularized by whole organ perfusion. Decellularized hearts were grossed to produce cardiac patches (n=9) or were recannulated in a customized closed apparatus with controlled temperature and gas exchange for recellularization (for whole organ recellularization, n=6). Expanded hiPSC-dECs were attached (74.9 ± 2.9%) to cardiac patches, forming vessel-like structures, surviving for at least 17 days in the patches. These patch studies were used to extrapolate the number of cells, the frequency of medium exchange and cell attachment and orientation needed for decellularized hearts. Based on these data, one hundred million hiPSC-dEC were perfused into the whole decellularized rabbit heart through the coronary trees and cultivated for 7 days. Recellularized hearts showed that cells selectively attached to the small and large vessels and the endocardium but were not observed outside of vessels. Conclusion: Together, these findings demonstrate that hiPSC-dEC expanded in a system can repopulate pediatric-size hearts by covering vessel walls and thus provide a favorable environment to prevent coagulation after transplantation.
Abstract 13721: The Monitoring of rSO2 Value During CPR is Useful for High-Quality CPR
Authors: Yoshihito Ogawa, Tadahiko Shiozaki, Tomoya Hirose, Mitsuo Ohnishi, Goro Tajima, Tetsuro Nishimura, Masashi Kishi, Hiroshi Ogura, Takeshi Shimazu
Journal: Circulation (2015)

[Background] Recently, the patients with out-of-hospital cardiac arrest are increasing. It is very important to do chest compression continuously for the return of spontaneous circulation (ROSC). But we can not but stop chest compression during checking pulse every few minutes. We reported that Regional cerebral Oxygen Saturation (rSO2) value was not elevated by manual chest compression and mechanical chest compression increased a little rSO2 value on CPR without ROSC and rSO2 value became a good parameter of ROSC in single center study. [Purpose] The purpose of this study is to evaluate clinical utility of rSO2 value during CPR in multicenter study. [Method] Retrospectively, we considered the rSO2 value of the out-of -hospital cardiac arrest patients from December 2012 to December 2014 in multicenter. During CPR, rSO2 were recorded continuously from the forehead of the patients by TOS-OR (Japan). CPR for patients with OHCA was performed according to the JRC-guidelines 2010. [Result] 252 patients with OHCA were included in this study. The rSO2 value on arrival, during CPR and ROSC were 44.4±8.9%, 45.4±9.7%, 58.6±9.2%. In ROSC, with rSO2 cutoff value of 52.7%, the specificity and sensitivity were 80% and 79%, respectively. The negative predict value was 99.2%, respectively. It means little possible to ROSC, if the rSO2 value is less than 52.7%. So, it may be possible to reduce the frequency of checking pulse during CPR. [Conclusion] The monitoring of rSO2 value could reduce the frequency of checking pulse during CPR and do chest compression continuously.
Insurance Coverage and Perinatal Health Care Use Among Low-Income Women in the US, 2015-2017
Authors: Lindsay K. Admon, Jamie R. Daw, Tyler N. A. Winkelman, Katy Backes Kozhimannil, Kara Zivin, Michele Heisler, Vanessa K. Dalton
Journal: JAMA Network Open (2021)

This cross-sectional study uses 2015-2017 data from the Pregnancy Risk Surveillance and Monitoring System to examine the association between health insurance coverage and use of perinatal health care among low-income women in the US.
FRI-215-Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: 144 weeks results of phase 3 trial
Authors: Hyung Joon Yim, Sang Hoon Ahn, Won Kim, Jin Mo Yang, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Soon Ho Um, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young-Suk Lim, Wan Sik Lee, Kwang-Hyub Han
Journal: Journal of Hepatology (2019)
Hypertrophic Cardiomyopathy Without Hypertrophy: An Emerging Pre-Clinical Subgroup Composed of Genetically Affected Family Members⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Barry J. Maron, Carolyn Y. Ho
Journal: JACC. Cardiovascular imaging (2009)
Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable esophagogastric junction adenocarcinoma: A retrospective study.
Authors: Toshiharu Hirose, Shun Yamamoto, Kotoe Oshima, Hidekazu Hirano, Natsuko Okita Tsuda, Hirokazu Shoji, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Narikazu Boku, Zyunya Oguma, Koshiro Ishiyama, Hiroyuki Daiko, Ken Kato
Journal: Journal of Clinical Oncology (2021)

209 Background: In Western countries, 5-FU plus leucovorin, oxaliplatin, docetaxel (DTX) (FLOT) is the standard perioperative treatment for resectable gastric adenocarcinoma and esophagogastric junction adenocarcinoma (EGJ-AC). Preoperative chemotherapy with DTX plus cisplatin and 5-FU (DCF) has been developed for esophageal squamous cell carcinoma in Japan. However, there have been few reports on the safety and efficacy of preoperative triple therapy for resectable EGJ-AC. Methods: The subjects of this retrospective study were patients (pts) with histologically confirmed resectable EGJ-AC who received preoperative DCF chemotherapy (DTX 70 mg/㎡ and cisplatin 70 mg/㎡ on day 1, and continuous infusion of 5-FU 750 mg/㎡/day on days 1–5, every 3 weeks with a maximum of three cycles) at our hospital from Jan 2015 to Apr 2020. We evaluated the completion rate of &gt;2 courses of DCF and R0 resection in all cases, and also examined histological response, progression-free survival (PFS), overall survival (OS), and adverse events during preoperative chemotherapy. Results: Thirty-two pts were included in this study, and the median observation period was 13.1 months (3.9–57.2). Characteristics were median age (range) 63 (42–80) years, PS 0/1 66/34%, clinical stage I/IIA/IIB/III/IVA/IVB (supraclavicular lymph node) 3/13/3/10/22/32/13%. Treatment completion rate was 84%. Histological response (grade 1a/1b/2/3) was obtained in 18/8/4/1 (58/26/13/3%) pts. Median PFS (95%CI) was 16.8 months (15.0–18.5), and median OS was not reached (3-year OS rate 73.8%). Grade &gt;3 adverse events were observed in 20(63%) pts (neutropenia in 14 [44%], febrile neutropenia in 4 [13%]). No treatment-related deaths occurred. Conclusions: Preoperative DCF chemotherapy for resectable EGJ-AC was well tolerated. Further investigation is required to evaluate the long-term efficacy of this treatment strategy.
FRI0253 Eosinophilic fasciitis: retrospective evaluation of 7 cases
Authors: E Tunc, V Inal, G Keser, T Pirildar, T Türk, K Aksu, Y Kabasakal, F Oksel, E Doganavsargil
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Eosinophilic fasciitis (EF) is a rare disorder characterised by scleroderma-like enduration of the skin, predominantly on the extremities and peripheral eosinophilia. Absence of Raynaud's phenomenon and visceral involvement are typical features. Histologic findings include fibrosis of muscle fascia and eosinophilic infiltration. Different clinical entities are reported in association with EF. Hereby, we aimed to present clinical characteristics of our cases. <h3>Objectives</h3> The medical data of 7 patients with EF (F/M:4/3; mean age 41.7 ± 19), who were followed up for 22.7 ± 19.6 months in Ege University Rheumatology department between January 1996 and December 2000. Mean disease duration was 11 ± 9.2 months on initial diagnosis. The diagnosis was made by en-block biopsy. Skin enduration was located on the lower and upper extremities in all cases. In one patient there was additional enduration on trunk. All cases had peripheral eosinophilia and hypergammaglobulinemia. Elevated muscle enzymes were present only in one case. High titer ANA positivity was present only in three female cases. 2 cases had carpal tunnel syndrome, one had interstitial eosinophilic pneumonia, one had pericarditis and Hashimato thyroiditis, one had vitiligo, one had type II DM which began simultaneously and one had psoriasis in association with EF. There were no history of any relevant medication and toxic material ingestion. No one had malignancy in the follow-up period. Initial treatment consisted of methylprednisolone (32 mg/day) and methotrexate (10 mg/week). Since in literature, high serum histamin levels and good response to H2 blockers were reported, ranitidine was also added to this treatment1. All the patients responded well; however one case was resistant to this treatment. D-penicillamine (150 mg/day) and colchicine (1 mg/day) treatment were added for this patient. Skin endurations regressed in all cases. Two patient had complete and the other five had partial remission. <h3>Methods</h3> <h3>Results</h3> <h3>Conclusion</h3> In conclusion, the diagnosis of EF should be always confirmed by en-block biopsy and presence of associated autoimmune pathologies should be kept in mind and searched. Malignancy should always be excluded. Response to appropriate treatment is generally satisfactory. <h3>Reference</h3> Naschitz JE, Boss JH, Misselevich I, Yesfurun D, Rosner I. The fasciitis-panniculitis syndromes. Clinical and pathologic features. Medicine (Baltimore) 1996;75(1):6–16